Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot - ballot International flag

This page is part of the Evidence Based Medicine on FHIR Implementation Guide (v1.0.0-ballot: STU1 Ballot 1) based on FHIR (HL7® FHIR® Standard) v5.0.0. . For a full list of available versions, see the Directory of published versions

Example EvidenceVariable: Therapeutic-dose anticoagulation with heparin

Active as of 2022-08-05

Generated Narrative: EvidenceVariable

Resource EvidenceVariable "7751" Version "12"

StructureDefinition Work Group: cds

url: https://fevir.net/resources/EvidenceVariable/7751

identifier: FEvIR Object Identifier: 7751

version: 1.0.0-ballot

name: Therapeutic_dose_anticoagulation_with_heparin

title: Therapeutic-dose anticoagulation with heparin

status: active

date: 2022-08-05 14:37:53+0000

publisher: HL7 International / Clinical Decision Support

contact: HL7 International / Clinical Decision Support: http://www.hl7.org/Special/committees/dss

description: Therapeutic-dose anticoagulation with unfractionated or low-molecular-weight heparin was administered according to local protocols for the treatment of acute venous thromboembolism for up to 14 days or until recovery; the latter was defined as hospital discharge or a discontinuation of supplemental oxygen for at least 24 hours.

copyright: https://creativecommons.org/licenses/by-nc-sa/4.0/

author: Brian S. Alper:

characteristic

definitionByCombination

code: any-of

characteristic

definitionCodeableConcept: ATTACC investigational arm: Therapeutic anticoagulation for 14 days (or until hospital discharge or liberation from the need for supplemental oxygen, whichever comes first) with preference for low-molecular weight heparin (LMWH), or alternative unfractionated heparin (UFH). LMWH dosed according to patient weight and creatinine clearance according to local practice and policy. For UFH, suggested target of aPTT 1.5 to 2.5 times the upper limit of normal or therapeutic anti-Xa levels. ()

timeFromEvent

characteristic

definitionCodeableConcept: ACTIV-4a investigational arm: Low-molecular weight heparin (LMWH) dosed according to patient weight and creatinine clearance. For UFH, suggested target of anti-Xa of 0.3-0.7 IU/ml or aPTT 1.5 to 2.5 times the upper limit of normal. ()

timeFromEvent

characteristic

definitionCodeableConcept: REMAP-CAP investigational arm: Dosed according to local hospital policy, practice, and guidelines for treatment of venous thromboembolism. Low-molecular weight heparin (LMWH) dosed according to patient weight. For UFH, suggested target for aPTT of 1.5 to 2.5 times the upper limit of normal or therapeutic anti-Xa levels. ()

timeFromEvent